Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Rhea-AI Summary
Corcept Therapeutics (NASDAQ: CORT) has announced it will release its second quarter financial results and provide a corporate update on July 29, 2024. The company will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on the same day. Participants must register in advance to receive a dial-in number and unique access PIN. A listen-only webcast will also be available. A replay of the call will be accessible on the Investors / Events section of Corcept.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CORT declined 0.03%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller.
Additionally, a listen-only webcast will be available by clicking here.
A replay of the call will be available on the Investors / Events tab of Corcept.com.
About Corcept Therapeutics
For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Corcept is headquartered in Menlo Park, California. For more information, visit Corcept.com.
CONTACT:
Investor inquiries:
ir@corcept.com
Media inquiries:
communications@corcept.com
www.corcept.com
FAQ
When will Corcept Therapeutics (CORT) release its Q2 2024 financial results?
What time is Corcept Therapeutics' (CORT) Q2 2024 earnings call scheduled for?
How can investors participate in Corcept Therapeutics' (CORT) Q2 2024 earnings call?
Where can I find a replay of Corcept Therapeutics' (CORT) Q2 2024 earnings call?
